The Pancreatic Enzymes After Gastrectomy Trial

November 9, 2026 updated by: Albrecht Hoffmeister, University of Leipzig

This trial evaluates the effects (e.g. on quality of life, weight) of NORTASE® compared to standard care of patients who have undergone gastrectomy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

188

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Berlin, Germany
        • Not yet recruiting
        • Allgemein- und Viszeralchirurgie; Sana Klinikum Berlin-Lichtenberg
        • Contact:
      • Borna, Germany
        • Recruiting
        • Sana Kliniken Leipziger Land GmbH, Klinik für Allgemein-, Viszeral-, MIC- und Gefäßchirurgie / Thoraxchirurgie
        • Contact:
      • Böblingen, Germany
        • Not yet recruiting
        • Kliniken Böblingen, Klinik für Allgemein-, Viszeral- und Kinderchirurgie
        • Contact:
      • Cottbus, Germany, 03048
        • Recruiting
        • Carl-Thiem-Klinikum Cottbus gGmbH; 4. Medizinische Klinik
        • Contact:
      • Essen, Germany
        • Recruiting
        • KEM | Evang. Kliniken Essen-Mitte gGmbH, Klinik für Internistische Onkologie
        • Contact:
      • Freiburg im Breisgau, Germany, 79106
        • Recruiting
        • UNIVERSITÄTSKLINIKUM FREIBURG Klinik für Allgemein- und Viszeralchirurgie Department Chirurgie
        • Contact:
      • Hamburg, Germany
        • Recruiting
        • Klinik für Allgemein-, Viszeral- und Thoraxchirurgie; Universitätsklinikum Hamburg-Eppendorf
        • Contact:
      • Heidelberg, Germany
      • Jena, Germany, 07740
        • Recruiting
        • Universitätsklinikum Jena, Allgemein-, Viszeral- und Gefäßchirurgie
        • Contact:
      • Leipzig, Germany, 04103
        • Recruiting
        • Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie und Pneumologie Universitätsklinikum Leipzig
        • Contact:
      • Leipzig, Germany
        • Recruiting
        • Klinikum St. Georg, Abteilung für Allgemein-, Viszeral- und Onkologische Chirurgie
        • Contact:
      • Nuremberg, Germany
        • Recruiting
        • Klinik für Allgemein-, Viszeral- und Thoraxchirurgie; Klinikum Nürnberg
        • Contact:
      • Tübingen, Germany
        • Recruiting
        • Klinik für Allgemeine-, Viszerale-, und Transplantationschirurgie; Universitätsklinikum Tübingen
        • Contact:
      • Ulm, Germany
        • Recruiting
        • Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Ulm
        • Contact:
      • Wesel, Germany
        • Not yet recruiting
        • Klinik für Innere Medizin - Gastroenterologie, Hämatologie und Onkologie; Evang. Krankenhaus
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Gastrectomy (total and partial distal); at least > 50 % of the stomach must be resected
  2. Age 18 or older
  3. Written informed consent

Exclusion Criteria:

  1. Indication for pancreas enzyme therapy
  2. Gastrectomy with palliative intention
  3. UICC (Union for International Cancer Control) Stage IV gastric malignancy
  4. Malnutrition of other aetiology
  5. Life expectancy < 12 months
  6. Known lactose intolerance
  7. Known hereditary galactose intolerance
  8. Patients on alpha-glucosidase inhibitors (AGIs)
  9. Acute pancreatitis
  10. Acute episode of chronic pancreatitis
  11. Known hypersensitivity to moulds (mould allergy) or any other ingredient of NORTASE®
  12. Participation in competing interventional trials may be allowed under circumstances
  13. Patients under legal supervision or guardianship
  14. Patients who are dependent on the investigator or the medical staff of the trial team or the coordinating investigator or the sponsor
  15. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial
  16. Pregnant or nursing women
  17. Suspected lack of compliance
  18. Patients who were already enrolled in the trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

10-15 capsules of placebo per day - over 6 months

Experimental: NORTASE®

10-15 capsules of NORTASE® per day - over 6 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease specific quality of life (QOL)
Time Frame: 6 months

This is the physical sub-score from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC-QLQ-C30) and ranges from 0 (lowest physical functioning) to 100 (highest physical functioning).

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nutritional supplementation or weight loss
Time Frame: 6 months

Proportion of patients who receive supplemental nutrition after the run-in period of 3 weeks or have > 10% weight loss at six months

6 months
Weight
Time Frame: 6 months

Percent weight-change at six months (weight in kilograms)

6 months
Serum haemoglobin
Time Frame: 6 months

Concentration of serum haemoglobin

6 months
Total protein
Time Frame: 6 months

Concentration of total protein

6 months
Albumin
Time Frame: 6 months

Concentration of albumin

6 months
Glucose
Time Frame: 6 months

Concentration of glucose

6 months
HbA1c
Time Frame: 6 months

Concentration of HbA1c

6 months
Cholesterol
Time Frame: 6 months

Concentration of cholesterol

6 months
Vitamin A
Time Frame: 6 months

Concentration of vitamin A

6 months
Vitamin B12
Time Frame: 6 months

Concentration of vitamin B12

6 months
Vitamin D
Time Frame: 6 months

Concentration of vitamin D

6 months
Vitamin E
Time Frame: 6 months

Concentration of vitamin E

6 months
Vitamin K
Time Frame: 6 months

Concentration of vitamin K

6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Faecal elastase-1
Time Frame: 6 months

Concentration of faecal elastase-1

6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Albrecht Hoffmeister, Prof. Dr., Universität Leipzig

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 24, 2024

Primary Completion (Estimated)

February 1, 2028

Study Completion (Estimated)

February 1, 2028

Study Registration Dates

First Submitted

September 8, 2023

First Submitted That Met QC Criteria

September 21, 2023

First Posted (Actual)

September 28, 2023

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PANEM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.